Border Bio specializes in helping emerging companies more effectively move their drug or vaccine candidates through preclinical and early-stage clinical development. Our specialty is working with companies with advanced therapeutics such as biologics (proteins and peptides), cell therapies, and gene therapies. We are experts in helping small companies achieve first-in-human studies rapidly and economically. This includes pursuit of “first in Canada” clinical trials that can accelerate translation to the clinic.

Our services include regulatory guidance and assistance with the planning and execution of nonclinical and clinical studies as well as manufacturing development.

We also help small biotech companies compete for Federal research grants and contracts and manage subsequent awards. Our specialization is countermeasure development addressing areas of strategic importance to the US government, including public health emergency response.